河南中医药大学,河南省郑州市金水东路156号,450046
zhengxk.2006@163.com,(0370)60190296
收稿:2022-03-05,
修回:2022-11-14,
纸质出版:2023-01-17
移动端阅览
张贝贝,曾梦楠,王亚玺等.典型升浮中药和沉降中药潜在作用靶点网络药理学及大鼠体内验证研究[J].中医杂志,2023,64(02):174-181.
ZHANG Beibei,ZENG Mengnan,WANG Yaxi,et al.Network Pharmacology and In Vivo Validation of Potential Targets of Typical Ascending and Floating, Descending and Sinking Chinese Medicinals[J].Journal of Traditional Chinese Medicine,2023,64(02):174-181.
张贝贝,曾梦楠,王亚玺等.典型升浮中药和沉降中药潜在作用靶点网络药理学及大鼠体内验证研究[J].中医杂志,2023,64(02):174-181. DOI: 10.13288/j.11-2166/r.2023.02.012.
ZHANG Beibei,ZENG Mengnan,WANG Yaxi,et al.Network Pharmacology and In Vivo Validation of Potential Targets of Typical Ascending and Floating, Descending and Sinking Chinese Medicinals[J].Journal of Traditional Chinese Medicine,2023,64(02):174-181. DOI: 10.13288/j.11-2166/r.2023.02.012.
目的
2
探究典型升浮中药和沉降中药的潜在作用靶点。
方法
2
通过中药系统药理学数据库与分析平台检索并筛选升浮中药(麻黄、柴胡、升麻、葛根、桔梗、薄荷)和沉降中药(葶苈子、旋覆花、刀豆、川牛膝、茯苓、苦杏仁、丁香)的靶点;以病位在表(风寒表证、风水水肿)、病位在里(痰饮停聚、肺水)、病势下陷(胃缓、心衰)、病势上逆(呕吐、肝阳上亢)在GeneCards数据库检索病症靶点。取升浮中药与病位在表、病势下陷病症的共有靶点,推测其可能为升浮中药的潜在作用靶点;取沉降中药与病位在里、病势上逆病症的共有靶点,推测其可能为沉降中药的潜在作用靶点。再进行动物实验验证:将140只雄性SD大鼠分为正常对照组、麻黄组(4.2 g/kg)、柴胡组(7 g/kg)、升麻组(7 g/kg)、葛根组(10.5 g/kg)、桔梗组(7 g/kg)、薄荷组(4.2 g/kg)、葶苈子组(7 g/kg)、旋覆花组(6.3 g/kg)、刀豆组(6.3 g/kg)、川牛膝组(7 g/kg)、茯苓组(10.5 g/kg)、苦杏仁组(7 g/kg)和丁香组(2.1 g/kg),每组10只,以1ml/100g灌胃体积连续灌胃相应药物14天。根据网络药理学研究结果,采用实时荧光定量PCR法检测大鼠肺组织中胰岛素生长因子2(IGF-2)、己糖激酶2(HK-2)、过氧化物酶体增殖物激活受体γ(PPAR-γ)、毒蕈碱乙酰胆碱受体M3(CHRM3)、毒蕈碱乙酰胆碱受体M1(CHRM1)和糖原合成酶激酶3β(GSK-3β)的mRNA水平;采用Western Blot法和免疫组化法检测CHRM3、CHRM1和PPAR-γ蛋白水平。
结果
2
网络药理学结果显示,升浮中药潜在作用靶点为IGF-2和HK-2,沉降中药潜在作用靶点有PPAR-γ、CHRM3、CHRM1和GSK-3β。mRNA及蛋白检测结果显示,与正常对照组比较,麻黄组、柴胡组、升麻组、葛根组、桔梗组、丁香组和刀豆组CHRM3水平均显著降低,苦杏仁组CHRM3水平显著升高(
P
<0.05或
P
<0.01);葛根组和桔梗组CHRM1水平显著降低,薄荷组、葶苈子组、旋覆花组、川牛膝组、茯苓组、丁香组、苦杏仁组和刀豆组CHRM1水平显著升高(
P
<0.05或
P
<0.01);麻黄组、升麻组、葛根组和桔梗组PPAR-γ水平显著降低,旋覆花组、川牛膝组、茯苓组、苦杏仁组PPAR-γ水平显著升高(
P
<0.05或
P
<0.01)。
结论
2
典型升浮中药和沉降中药潜在作用靶点主要为CHRM3、CHRM1和PPAR-γ。
Objective
2
To explore the potential action targets of typical ascending and floating Chinese medicinals and descending and sinking medicinals.
Methods
2
Firstly, the targets of ascending and floating Chinese medicinals including Mahuang (
Herba Ephedrae
), Chaihu (
Radix Bupleuri
), Shengma (
Rhizoma Cimicifuga
), Gegen (
Radix Puerariae Lobatae
), Jiegeng (
Radix Platycodonis
), Bohe (
Herba Menthae
), and descending and sinking Chinese medicinals including Tinglizi (
Semen Lepidii
), Xuanfuhua (
Flos Inulae
), Daodou (
Semen Canavaliae
), Chuanniuxi (
Radix Cyathulae
), Fuling (
Poria
), Kuxinren (
Semen Armeniacae Amarum
), and Dingxiang (
Flos Caryophylli
) were searched and selected through the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform. Disease targets were searched in GeneCards database with the keywords “wind-cold exterior syndrome” and “wind-water edema” (the disease is located at the exterior), "phlegm-rheum retention” and “pulmonary edema” (the disease is located at the interior), “down-bearing stomachache” and “heart failure” (sinking tendency of disease), and “vomitting” and “liver-yang hyperactivity” (upward reversal of disease tendency). The intersection genes of ascending and floating Chinese medicinals and the diseases location at the exterior and sinking tendency of disease may be the potential targets for the ascending and floating Chinese medicinals; the intersection genes of descending and sinking Chinese medicinals and the disease location at the interior and the upward reversal of disease tendency may be the potential targets for descending and sinking Chinese medicinals. Animal validation experiment: 140 male SD rats were divided into normal control group, Mahuang (4.2 g/kg) group, Chaihu (7 g/kg) group, Shengma (4.2 g/kg) group, Gegen (10.5 g/kg) group, Jiegeng (7 g/kg) group, Bohe (4.2 g/kg) group, Tinglizi (7 g/kg) group, Xuanfuhua (6.3 g/kg) group, Daodou (6.3 g/kg) group, Chuanniuxi (7 g/kg) group, Fuling (10.5 g/kg) group, Kuxingren (7 g/kg) group and Dingxiang (2.1 g/kg) group, with 10 rats in each group. Corresponding Chinese medicinals were given by gavage at the volume of 1 ml/100 g for 14 days. According to the results of network pharmacology, real-time quantitative PCR was used to detect the mRNA levels of insulin-like growth factor 2 (IGF-2), hexokinase2 (HK-2), peroxisome proliferator-activated receptor γ (PPAR-γ), cholinergic receptor muscarinic 3 (CHRM3), muscarinic cholinergic receptor 1 (CHRM1) and glycogen synthase kinase-3β (GSK-3β). Western Blot and immunohistochemical methods were used to detect the protein levels of CHRM3, CHRM1 and PPAR-γ.
Results
2
Using network pharmacology, the potential targets of ascending and floating medicinals were IGF-2 and HK-2, and those of descending and sinking medicinals were PPAR-γ, CHRM3, CHRM1 and GSK-3β. The detection of mRNA and proteins showed that compared to normal control group, there were significantly lower CHRM3 levels in Mahuang group, Chaihu group, Shengma group, Gegen group, Jiegeng group, Dingxiang group and Daodou group, while higher CHRM3 level in Kuxingren group (
P
<0.05 or
P
<0.01); Gegen and Jiegeng groups had decreased level of CHRM1, while Bohe, Tinglizi, Xuanfuhua, Chuanniuxi, Fuling, Dingxiang, Kuxingren and Daodou groups had increased level of CHRM1 (
P
<0.05 or
P
<0.01); Mahuang, Shengma, Gegen and Jiegeng groups could significantly decrease the level of PPAR-γ, while Xuanfuhua, Chuanniuxi, Fuling and Kuxingren groups could increase the level of PPAR-γ (
P
<0.05 or
P
<0.01).
Conclusion
2
The potential targets of typical ascending and floating as well as descending and sinking Chinese medicinals are mainly CHRM3, CHRM1 and PPAR-γ.
陈勇 , 杨敏 , 闵志强 , 等 . 析中药升降浮沉渊源流变 [J]. 四川中医 , 2016 , 34 ( 10 ): 17 - 20 .
史伟 . 中药的升降浮沉 [J]. 中华肾病研究电子杂志 , 2018 , 7 ( 4 ): 151 - 155 .
项丽玲 , 李艳 , 苗明三 . 升降浮沉药性现代药理研究的分析与思考 [J]. 中华中医药杂志 , 2019 , 34 ( 11 ): 5269 - 5272 .
钟赣生 . 中药学 [M]. 北京 : 中国中医药出版社 , 2021 : 27 - 28 .
克迎迎 , 袁培培 , 王小兰 , 等 . 桑白皮化学拆分组分对正常大鼠物质代谢与能量代谢的影响 [J]. 世界中医药 , 2015 , 10 ( 12 ): 1847 - 1853 .
刘璐 , 严季澜 , 李柳骥 . 张元素、陈士铎对药物升降浮沉理论认识的比较 [J]. 河南中医 , 2015 , 35 ( 9 ): 2017 - 2019 .
傅阳 , 袁培培 , 侯颖 , 等 . 基于GnRHR信号通路探讨升浮药麻黄与沉降药葶苈子干预哮喘作用差异 [J]. 中华中医药杂志 , 2022 , 37 ( 5 ): 2553 - 2562 .
郝万山 . 伤寒论讲稿 [M]. 北京 : 人民卫生出版社 , 2008 : 32 - 35 .
韦绪性 , 杨德全 . 中医内科学 [M]. 北京 : 中国中医药出版社 , 2015 : 300 - 301 .
刘燕池 . 中医基础理论讲稿 [M]. 北京 : 人民卫生出版社 , 2008 : 177 - 179 .
韦绪性 , 杨德全 . 中医内科学 [M]. 北京 : 中国中医药出版社 , 2015 : 94 - 96 .
余小萍 , 方祝元 . 中医内科学 [M]. 上海 : 上海科学技术出版社 , 2018 : 182 .
唐旭东 , 张声生 , 温艳东 . 常见脾胃病中医临床实践指南 [M]. 北京 : 科学技术文献出版社 , 2019 : 165 - 170 .
陈蕾蕾 . 中医呕吐病症源流与古今文献研究 [M]. 贵阳 : 贵州科技出版社 , 2020 : 1 .
郑筱萸 . 中药新药临床研究指导原则(试行) [M]. 北京 : 中国医药科技出版社 , 2002 : 74 - 75 .
钟赣生 . 中药学 [M]. 北京 : 中国中医药出版社 , 2021 : 56 .
国家药典委员会 . 中华人民共和国药典(2020年版) [M]. 北京 : 中国医药科技出版社 , 2020 : 12 - 394 .
陈奇 . 中药药理研究方法学 [M]. 北京 : 人民卫生出版社 , 1996 : 1103 .
丛馨 , 闵赛南 , 吴立玲 , 等 . 激活毒蕈碱乙酰胆碱受体调控下颌下腺分泌的机制研究 [J]. 北京大学学报(医学版) , 2019 , 51 ( 103 ): 390 - 396 .
MAEDA Y , HIZAWA N , JINUSHI E , et al . Polymorphisms in the cholinergic receptor, muscarinic 1 (CHRM1) gene confer susceptibility to asthma in Japanese [J]. J Allergy Clin Immunol , 2006 , 117 ( 2 ): S200 .
陈超 , 张瑞芬 , 张海荣 . PPAR-γ与动脉粥样硬化及其危险因素的相关研究进展 [J]. 中国循证心血管医学杂志 , 2021 , 13 ( 9 ): 1146 - 1147 .
0
浏览量
4
下载量
2
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号